Go Pro

BioNTech (BNTX) 10K Form and Latest SEC Filings 2026

BioNTech logo
$102.07 -9.33 (-8.38%)
As of 08/28/2026 04:00 PM Eastern

Latest BioNTech SEC Filings & Recent Activity

BioNTech (NASDAQ:BNTX) has submitted 378+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in BioNTech's financial statements. The most recent filing was a Form 6-K submitted on August 28, 2026.

20-F
BioNTech Files Annual Report on Mar. 10, 2026

The 20-F contains BioNTech's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

BioNTech SEC Filing History

Browse BioNTech's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
08/28/2026 8:06 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/27/2026 3:54 PM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/20/2026 6:36 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/04/2026 6:00 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/04/2026 6:01 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/03/2026 5:54 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/26/2026 8:08 AM
BioNTech (1776985) Issuer
Schaffert Susanne (1938363) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/26/2026 8:10 AM
BioNTech (1776985) Issuer
Low-Friedrich Iris Katharina (2138283) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/08/2026 7:01 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2026 6:59 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/22/2026 7:03 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2026 3:04 PM
BioNTech (1776985) Subject
Sahin Ugur (2123975) Filed by
Form SCHEDULE 13G/A
05/14/2026 4:22 PM
ATHOS KG (1802897) Filed by
BioNTech (1776985) Subject
Form SCHEDULE 13G/A
05/13/2026 3:02 PM
BioNTech (1776985) Issuer
Hanekamp Annemarie (2118987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2026 3:03 PM
BioNTech (1776985) Issuer
Jimenez Kylie (2123971) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2026 3:05 PM
BioNTech (1776985) Issuer
Poetting Sierk (1955589) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 5:56 PM
BioNTech (1776985) Subject
Medine GmbH (1803150) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/07/2026 7:20 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/05/2026 5:47 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/05/2026 5:49 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2026 3:02 PM
BioNTech (1776985) Issuer
Poetting Sierk (1955589) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:02 PM
BioNTech (1776985) Issuer
Sahin Ugur (2123975) Reporting
Form 3/A
04/13/2026 6:55 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/25/2026 4:55 PM
BioNTech (1776985) Issuer
Jimenez Kylie (2123971) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/25/2026 4:57 PM
BioNTech (1776985) Issuer
Ryan James Timothy Patrick (2123964) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/25/2026 4:58 PM
BioNTech (1776985) Issuer
Zapata Gomez Ramon (2123980) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/25/2026 5:00 PM
BioNTech (1776985) Issuer
Sahin Ugur (2123975) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/25/2026 5:01 PM
BioNTech (1776985) Issuer
Staudigl Rudolf (2124147) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/25/2026 5:03 PM
BioNTech (1776985) Issuer
Morawietz Anja (2124146) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/25/2026 5:04 PM
BioNTech (1776985) Issuer
Blackwood Nicola Claire (2124143) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/24/2026 4:09 PM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/18/2026 4:36 PM
BioNTech (1776985) Issuer
Tureci Ozlem (2044235) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 4:39 PM
BioNTech (1776985) Issuer
Jeggle Helmut Wolfgang (1982614) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 4:41 PM
BioNTech (1776985) Issuer
Poetting Sierk (1955589) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 4:43 PM
BioNTech (1776985) Issuer
Motschmann Michael (2118249) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/11/2026 7:02 AM
BioNTech (1776985) Subject
Poetting Sierk (1955589) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/10/2026 5:53 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/10/2026 5:55 AM
BioNTech (1776985) Filer
Form 20-F
Registration statement / Annual report / Transition report  
03/10/2026 5:34 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/12/2026 7:17 AM
BioNTech (1776985) Subject
Medine GmbH (1803150) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/28/2026 7:10 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)

A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel

Click here to learn this company's name for free today
01/12/2026 5:57 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/06/2026 5:02 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/18/2025 3:15 PM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/18/2025 3:16 PM
BioNTech (1776985) Filed by
CureVac N.V. (1809122) Subject
Form SC TO-T/A
12/09/2025 6:25 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/08/2025 5:37 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/03/2025 3:50 PM
BioNTech (1776985) Filed by
CureVac N.V. (1809122) Subject
Form SC TO-T/A
11/28/2025 6:10 AM
BioNTech (1776985) Subject
Tureci Ozlem (2044235) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/26/2025 3:33 PM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/26/2025 3:34 PM
BioNTech (1776985) Filed by
CureVac N.V. (1809122) Subject
Form 425
11/13/2025 7:23 AM
BioNTech (1776985) Subject
Medine GmbH (1803150) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/12/2025 7:00 AM
BioNTech (1776985) Filed by
CureVac N.V. (1809122) Subject
Form 425
11/12/2025 7:01 AM
BioNTech (1776985) Filed by
CureVac N.V. (1809122) Subject
Form 425
11/12/2025 6:45 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/05/2025 3:52 PM
BioNTech (1776985) Subject
Jeggle Helmut Wolfgang (1982614) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/03/2025 5:49 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/03/2025 5:50 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/22/2025 3:27 PM
BioNTech (1776985) Filed by
CureVac N.V. (1809122) Subject
Form SC TO-T/A
10/22/2025 3:05 PM
BioNTech (1776985) Filed by
CureVac N.V. (1809122) Subject
Form 425
10/22/2025 3:01 PM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/22/2025 3:03 PM
BioNTech (1776985) Filed by
CureVac N.V. (1809122) Subject
Form 425
10/21/2025 3:29 PM
BioNTech (1776985) Filed by
CureVac N.V. (1809122) Subject
Form SC TO-T
10/21/2025 3:06 PM
BioNTech (1776985) Filer
Form F-4/A
10/01/2025 8:05 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/08/2025 3:40 PM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/08/2025 6:01 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/05/2025 3:41 PM
ATHOS KG (1802897) Reporting
BioNTech (1776985) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/05/2025 5:44 AM
BioNTech (1776985) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

BioNTech SEC Filings - Frequently Asked Questions

BioNTech (BNTX) has submitted 378+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

BioNTech's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on BioNTech's financial statements page.

The most recent filing was a Form 6-K submitted on August 28, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:BNTX are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 8/28/2026. New filings are added as they're published.
From Our Partners